3-氰基-3-苯基丙酮酸乙酯 | 6362-63-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氰基-3-苯基丙酮酸乙酯
• 中文别名: 乙基-3-氰基-3-苯丙酮酸
• 英文名称: ethyl 3-cyano-3-phenylpyruvate
• 英文别名: Ethyl-3-cyano-3-phenylpyruvat；Aethyl-3-cyano-3-phenylpyruvat；3-Cyan-3-phenyl-brenztraubensaeure-ethylester；α-Cyan-phenyl-brenztraubensaeure-aethylester；ethyl 3-cyano-2-oxo-3-phenylpropanoate
• CAS: 6362-63-6
• 化学式: C₁₂H₁₁NO₃
• mdl: MFCD00019801
• 分子量: 217.224
• InChiKey: YWNRATDDUSMBPR-UHFFFAOYSA-N

物化性质

• 熔点：
  124-128 °C (lit.)
• 稳定性/保质期：

  常温常压下稳定，是一种白色晶体状粉末。

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  67.2
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2926909090
• WGK Germany：
  3
• 储存条件：
  避光，存放在阴凉干燥处，并密封保存。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Ethyl 3-cyano-3-phenylpyruvate
CAS-No. : 6362-63-6
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
Not a hazardous substance or mixture according to EC-directives 67/548/EEC or 1999/45/EC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C12H11NO3
Molecular Weight : 217,22 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 124 - 128 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

AI3-15927是一种生物化学物质。

反应信息

• 作为反应物：
  描述：

  3-氰基-3-苯基丙酮酸乙酯 在 溶剂黄146 作用下， 以 水 为溶剂， 生成 2-(p-Chlorphenyl)-5-phenyl-3,4-dioxo-adiponitril
  参考文献：
  名称：

  Tetramic acid analogs of pulvinic acid

  摘要：

  通过用碱金属低级烷氧化物处理相应的四聚酸内酯，制备具有抗关节炎活性的四聚酸类脉枝酸类似物。

  公开号：

  US03931207A1
• 作为产物：
  描述：

  苯乙腈 在 甲醇 、 sodium hydroxide 、 乙醚 、 sodium 作用下， 生成 3-氰基-3-苯基丙酮酸乙酯
  参考文献：
  名称：

  The Condensation of Oxalic Esters with Benzyl Cyanide

  摘要：

  DOI：

  10.1021/ja01332a040

文献信息

• Biocatalytic Cascade for the Synthesis of Enantiopure β-Azidoalcohols and β-Hydroxynitriles
  作者：Joerg H. Schrittwieser、Iván Lavandera、Birgit Seisser、Barbara Mautner、Wolfgang Kroutil

  DOI：10.1002/ejoc.200900091

  日期：2009.5

  one-pot reaction sequence starting from prochiral α-chloroketones leading to enantiopure β-azidoalcohols and β-hydroxynitriles is described. Asymmetric bioreduction of α-chloroketones by hydrogen transfer catalysed by an alcohol dehydrogenase (ADH) established the stereogenic centre in the first step to furnish enantiopure chlorohydrin intermediates. Subsequent biocatalysed ring closure to the epoxide

  描述了从前手性 α-氯酮开始导致对映纯 β-叠氮醇和 β-羟基腈的三步、两酶、一锅反应序列。通过由醇脱氢酶 (ADH) 催化的氢转移对 α-氯酮进行不对称生物还原，在第一步中建立了立体中心，以提供对映纯的氯醇中间体。随后通过非选择性卤代醇脱卤酶 (Hhe) 催化环氧化物的生物催化闭环和用叠氮化物 N3- 或氰化物 CN- 的亲核开环进行完全保留构型，得到对映体纯的 β-叠氮醇和 β-羟基腈，分别。合成了各种光学纯 β-叠氮醇和 β-羟基腈的两种对映异构体。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)
• Compounds for treating and preventing cognitive diseases and depression
  申请人：Hoffmann-La Roche Inc.

  公开号：US05011849A1

  公开（公告）日：1991-04-30

  Ethylenediamine monoamides of the formula R--CO--NH--CH.sub.2 --CH.sub.2 --NH.sub.2 I wherein R is one of groups ##STR1## in which R.sup.1 is phenyl monohalophenyl, monolower-alkylphenyl, monolower-alkoxypheynl, monotrifluoromethylphenyl, monocyanophenyl or monoaryl-lower-alkoxyphenyl, dihalophenyl, furyl, thienyl or monohalothienyl, R.sup.2 is hydrogen, halogen or amino, R.sup.3, R.sup.5 and R.sup.7 each are phenyl, monohalophenyl, dihalophenyl, thienyl, furyl or monohalofuryl, R.sup.4 and R.sup.6 each are hydrogen or amino and R.sup.8 is hydrogen or lower-alkyl, as well as their pharmaceutically usable acid addition salts are disclosed. The compounds have monoamine oxidase inhibiting properties with low toxicity and are useful for the treatment of depressive states and cognitive disorders.

  公开了具有单胺氧化酶抑制性能且具有低毒性的乙二胺单酰胺化合物，其化学式为R--CO--NH--CH.sub.2 --CH.sub.2 --NH.sub.2，其中R是下列基团之一：##STR1## 其中R.sup.1为苯基、单卤苯基、单较低烷基苯基、单较低烷氧基苯基、单三氟甲基苯基、单氰基苯基或单芳基-较低烷氧基苯基、双卤苯基、呋喃基、噻吩基或单卤噻吩基，R.sup.2为氢、卤素或氨基，R.sup.3、R.sup.5和R.sup.7各自为苯基、单卤苯基、双卤苯基、噻吩基、呋喃基或单卤呋喃基，R.sup.4和R.sup.6各自为氢或氨基，R.sup.8为氢或较低烷基，以及它们的药用可用酸盐。这些化合物具有单胺氧化酶抑制性能，低毒性，可用于治疗抑郁状态和认知障碍。
• Maleic anhydride derivatives used as conjugation agents of anti-tumor
  申请人：Universite Laval

  公开号：US05140013A1

  公开（公告）日：1992-08-18

  The present invention relates to anti-tumor-conjugation agent-protein compounds of the general formula I: ##STR1## wherein, R.sub.1 and R.sub.2 are each independently selected from hydrogen atom, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-6 carboxyalkyl, phenyl, or phenyl substituted by at least one of hydroxy, halogen, lower alkyl, lower alkoxy, or nitro, with the proviso that R.sub.1 and R.sub.2 cannot be simultaneously a hydrogen, and when one of R.sub.1 or R.sub.2 is a hydrogen, the other one cannot be --CH.sub.2 COOH; A is the residue of an anti-tumor agent containing at least one amino group available to form an amide bound; and B is a free .epsilon.-lysine containing residue selected from a peptide or a protein.

  本发明涉及一般式I的抗肿瘤共轭剂-蛋白化合物：其中，R.sub.1和R.sub.2分别独立地选择自氢原子、C.sub.1-4烷基、C.sub.1-4烷氧基、C.sub.1-6羧基烷基、苯基或至少一个羟基、卤素、低烷基、低烷氧基或硝基取代的苯基，但R.sub.1和R.sub.2不能同时为氢，当R.sub.1或R.sub.2之一为氢时，另一个不能为--CH.sub.2COOH；A是含有至少一个氨基可用于形成酰胺键的抗肿瘤剂的残基；B是选择自肽或蛋白的自由ε-赖氨酸残基。
• Anti-arthritic compositions comprising N-heterocyclic pulvinic acid
  申请人：SmithKline Corporation

  公开号：US03947580A1

  公开（公告）日：1976-03-30

  N-Heterocyclic pulvinic acid amides having antiarthritic activity are prepared by treating the corresponding pulvinic acid with a heterocyclic amine.

  通过将相应的脉脉酸与杂环胺处理，制备具有抗关节炎活性的N-杂环脉脉酸酰胺。
• Ester derivatives of pulvinic acid
  申请人：SmithKline Corporation

  公开号：US03944571A1

  公开（公告）日：1976-03-16

  Pharmaceutical compositions having anti-arthritic activity comprising an ester derivative of pulvinic acid and methods of producing anti-arthritic activity by administering internally said compositions. Certain of the pulvinic acid derivatives are novel compounds per se.

  具有抗关节炎活性的药物组合物包括蒲尔维酸酯衍生物，并通过内部给予这些组合物来产生抗关节炎活性的方法。其中一些蒲尔维酸衍生物是新颖的化合物本身。